These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37692364)

  • 1. Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer.
    Parent P; Marcq G; Adeleke S; Turpin A; Boussios S; Rassy E; Penel N
    Ther Adv Med Oncol; 2023; 15():17588359231192402. PubMed ID: 37692364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver.
    Stinchcombe TE
    Transl Lung Cancer Res; 2023 Jan; 12(1):158-167. PubMed ID: 36762068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology.
    Criscitiello C; Guerini-Rocco E; Viale G; Fumagalli C; Sajjadi E; Venetis K; Piciotti R; Invernizzi M; Malapelle U; Fusco N
    Anticancer Agents Med Chem; 2022; 22(4):787-800. PubMed ID: 34229592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
    Buder-Bakhaya K; Hassel JC
    Front Immunol; 2018; 9():1474. PubMed ID: 30002656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability.
    Ratovomanana T; Nicolle R; Cohen R; Diehl A; Siret A; Letourneur Q; Buhard O; Perrier A; Guillerm E; Coulet F; Cervera P; Benusiglio P; Labrèche K; Colle R; Collura A; Despras E; Le Rouzic P; Renaud F; Cros J; Alentorn A; Touat M; Ayadi M; Bourgoin P; Prunier C; Tournigand C; Fouchardière C; Tougeron D; Jonchère V; Bennouna J; de Reynies A; Fléjou JF; Svrcek M; André T; Duval A
    Ann Oncol; 2023 Aug; 34(8):703-713. PubMed ID: 37269904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
    Lin ZF; Qin LX; Chen JH
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
    Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
    Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.
    Hayes DF; Herbst RS; Myles JL; Topalian SL; Yohe SL; Aronson N; Bellizzi AM; Basu Roy U; Bradshaw G; Edwards RH; El-Gabry EA; Elvin J; Gajewski TF; McShane LM; Oberley M; Philip R; Rimm DL; Rosenbaum JN; Rubin EH; Schlager L; Sherwood SW; Stewart M; Taube JM; Thurin M; Vasalos P; Laser J
    JCO Precis Oncol; 2022 Nov; 6():e2200454. PubMed ID: 36446042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
    Costantini A; Takam Kamga P; Dumenil C; Chinet T; Emile JF; Giroux Leprieur E
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
    Lavoie JM; Black PC; Eigl BJ
    J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
    Honrubia-Peris B; Garde-Noguera J; García-Sánchez J; Piera-Molons N; Llombart-Cussac A; Fernández-Murga ML
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503087
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy-related biomarkers: Confirmations and uncertainties.
    Catalano M; Iannone LF; Nesi G; Nobili S; Mini E; Roviello G
    Crit Rev Oncol Hematol; 2023 Dec; 192():104135. PubMed ID: 37717881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs).
    Giustini N; Bazhenova L
    Lung Cancer (Auckl); 2021; 12():21-34. PubMed ID: 33790679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research status on immunotherapy trials of gastric cancer.
    Liang C; Wu HM; Yu WM; Chen W
    World J Clin Cases; 2021 Jul; 9(21):5782-5793. PubMed ID: 34368297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.